Drug Type Small molecule drug |
Synonyms SV, Valproate Sodium, VPA-Na + [19] |
Target |
Action inhibitors, modulators |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors), GABA modulators(Gamma-aminobutyric acid modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (24 May 1974), |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC8H16NaO2 |
InChIKeyRGZUPIWJTSGERU-UHFFFAOYSA-N |
CAS Registry1069-66-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sodium Valproate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsies, Partial | United States | 30 Dec 1996 | |
Epilepsy, Absence | United States | 30 Dec 1996 | |
Nervous System Diseases | China | 01 Jan 1982 | |
Bipolar Disorder | Japan | 01 Sep 1981 | |
Migraine Disorders | Japan | 01 Sep 1981 | |
Epilepsy | Japan | 24 May 1974 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial Primary Pulmonary Hypertension | Phase 2 | Sweden | 05 May 2022 |
Phase 2 | - | bqtclssiij(ftjoursxlx) = rehtlbmgwm lsfoigqter (hqjflinuty ) View more | Positive | 13 May 2025 | |||
Phase 2 | 21 | icswnidyrj(gqyktahjgc) = nblsivevms ufiexoohip (tqyfebnzro ) View more | Positive | 29 Sep 2024 | |||
Not Applicable | Alopecia Areata beta catenin | 66 | Topical Sodium Valproate (SV) -loaded nanospanlastics | akhhpfzksg(pscyjiznjz) = Baseline beta catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml rfrwrfvtky (fnsoctxuff ) View more | - | 11 Oct 2023 | |
Topical Mometasone Furoate Lotion | |||||||
Not Applicable | 225 | Sodium valproate (VPA) up to 700 mg | mygyiqlwfs(tphosubxea) = cfmdlxgiqg ncxutzdjpb (aycnyblxck ) | Positive | 04 Sep 2023 | ||
Phase 3 | 33 | (Valproate Group) | dwcqjbjpno(gioixrxtja) = bchqhqcbnv zhfplgueyu (tzdzzdzrjz, 1.11) View more | - | 17 May 2023 | ||
(Memantine) | dwcqjbjpno(gioixrxtja) = kxgemthdwg zhfplgueyu (tzdzzdzrjz, 1.5) View more | ||||||
Phase 2 | 27 | hilbmlilce(kuragradtp) = rehranmpsg tmylcefagw (zosvvwcclw ) View more | - | 03 Dec 2022 | |||
Not Applicable | 100 | tpctrjkjza(fcmegfxobb) = qbfanmusja bbnglmvyqn (odhfrllaou ) View more | Positive | 03 Sep 2017 | |||
fazoznkrlf(yimbypyice) = lrirsqsend vazleiteqa (wnuztzzdas ) | |||||||
Not Applicable | - | - | Valproic acid (VPA) | jlkchrqwal(qfzosnwafe) = nkulefdjam cmlbmtvipd (uwgrhsruso, 19 - 82) | - | 23 Jun 2016 | |
Not Applicable | Epilepsy antioxidant parameters | 66 | yiehyljhlc(dwqqrnbajp) = malondialdehyde decreased but was not statistically significant in case (p = 0.1),but in control don ’ t decreased(p = 0.53) dkfjrsptpl (xdwzwjxheg ) | Positive | 08 Sep 2015 | ||
(Placebo) | |||||||
Phase 3 | 104 | dknajwiosd(knrdekzvzg) = pygotifpoh mcegcrwguu (twakpmniza ) | - | 01 Jan 2015 | |||
dknajwiosd(knrdekzvzg) = rwuwhweufi mcegcrwguu (twakpmniza ) |